News & Blog - English
All you need to know
Latest Press Releases:
News
VivaScope Technology Enables Faster Diagnoses in Innovative Kidney Clinic in Cambridge
Munich / Cambridge, March 10, 2026 – VivaScope GmbH, a leading provider of confocal imaging systems for digital pathology, marks an important milestone for the future of rapid cancer diagnostics. At the “one-stop” kidney clinic at Addenbrooke’s Hospital in Cambridge, the VivaScope 2500 confocal microscope is now being used to assess biopsy samples directly on site, enabling clinicians to obtain diagnostic insights within minutes. Early results demonstrate a remarkable 91.7% concordance between diagnoses made using the confocal microscope and the final pathology results.
News
5th Generation: Ex Vivo 2500 for Instant Digital Pathology
Munich, 26th September 2025 – VivaScope is happy to announce the launch of the new Generation 5 Ex Vivo. This innovative generation offers significant technological improvements that will improve one more time the workflow for pathologists, pulmonoligists and dermatologists. With Generation 5, we have taken the Ex Vivo VivaScope 2500 to the next level by implementing advanced technologies starting with optimised slide handling, through new imaging modes, to a completely new and larger objective.
News
Cost–Benefit Analysis of In Vivo Reflectance Confocal Microscopy for Melanoma Diagnosis in a Real-World Clinical Setting
In this publication, the authors aimed to apply a cost–benefit analysis through a micro-costing approach to results from their randomized clinical trial to demonstrate the economic impact of the VivaScope® 1500 in routine clinical practice. This model was applied to regional and national data to estimate wider cost–benefit analyses.
Latest Publications
News
Economic value of the VivaScope 1500 In Vivo microscope
Extensive large-scale clinical trial demonstrated the therapeutic & economic value of the VivaScope 1500 In Vivo microscope in early diagnosis of Melanoma lesions.
News
Cost–Benefit Analysis of In Vivo Reflectance Confocal Microscopy for Melanoma Diagnosis in a Real-World Clinical Setting
In this publication, the authors aimed to apply a cost–benefit analysis through a micro-costing approach to results from their randomized clinical trial to demonstrate the economic impact of the VivaScope® 1500 in routine clinical practice. This model was applied to regional and national data to estimate wider cost–benefit analyses.
News
RCM at Evidence level 1b: Highest level possible
Febuary 2, 2025 – Reflectance Confocal Microscopy (RCM) has gained increasing importance in dermatological diagnostics in recent years. This non-invasive method enables a detailed real-time visualization of the skin layers and thus provides a precise assessment of skin lesions. RCM has proven to be particularly useful for improving diagnostic accuracy in lesions that are difficult to classify clinically or dermatoscopically.
In the latest European guidelines for skin cancer diagnostics, RCM has now been officially classified as level 1b evidence. This means that the method is based on the highest level of evidence, which underlines the importance and reliability of this technology. According to the guidelines, reflectance confocal microscopy should be used in particular for the further assessment of skin lesions that appear uncertain during visual inspection or dermatoscopy, provided that the technique is available.